Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Equity Average (2017 - 2025)

Autolus Therapeutics' Equity Average history spans 9 years, with the latest figure at $221.8 million for Q4 2025.

  • For Q4 2025, Equity Average fell 50.95% year-over-year to $221.8 million; the TTM value through Dec 2025 reached $221.8 million, down 50.95%, while the annual FY2025 figure was $302.7 million, 12.37% up from the prior year.
  • Equity Average reached $221.8 million in Q4 2025 per AUTL's latest filing, down from $306.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $554.9 million in Q2 2024 to a low of $146.0 million in Q4 2023.
  • Average Equity Average over 5 years is $308.1 million, with a median of $282.8 million recorded in 2023.
  • Peak YoY movement for Equity Average: skyrocketed 209.7% in 2024, then tumbled 50.95% in 2025.
  • A 5-year view of Equity Average shows it stood at $261.7 million in 2021, then fell by 12.14% to $229.9 million in 2022, then crashed by 36.5% to $146.0 million in 2023, then surged by 209.7% to $452.1 million in 2024, then crashed by 50.95% to $221.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Equity Average are $221.8 million (Q4 2025), $306.0 million (Q3 2025), and $358.8 million (Q2 2025).